Pengbo Guo

Head of Product Development CybernaX Bio

I specialize in lipid nanoparticle (LNP) technologies for nucleic acid delivery, RNA therapeutics, and translational development—spanning from early discovery through GLP-enabling studies to IND filing and strategic commercialization. My expertise lies in engineering next-generation delivery systems, with a focus on novel ionizable lipids, PEG-lipid alternatives, inhalable LNPs, and extrahepatic targeting. At CybernaX Biotechnologies, I lead both product development and business development functions. We are actively seeking strategic partnerships, R&D collaborations, and venture investment to accelerate our growth and impact. CybernaX is a cutting-edge biotechnology company dedicated to advancing delivery platforms for nucleic acid therapeutics. With a robust proprietary lipid library, our innovations support a wide range of applications—including vaccines, oncology, rare diseases, gene editing, early diagnostics, and novel administration routes such as pulmonary delivery. We are committed to enabling transformative RNA-based medicines for patients with unmet needs globally.

Seminars

Thursday 18th February 2027
AI-Driven Next-Generation Ionisable Lipid Development & Screening Strategies for Improved Transfection Efficiency & Endosomal Escape
1:00 pm
  • Leveraging machine learning & AI-driven approaches, from foundation-model pretraining to closed-loop active learning, to accelerate novel ionisable lipid identification from limited datasets
  • Addressing endosomal escape & payload–carrier compatibility through rational lipid design & formulation optimisation at reduced RNA doses
  • Balancing potency, safety & developability when transitioning from research-scale to GMP-ready lipid platforms, carrying model-derived knowledge into process scale-up & CMC
  • Screening novel ionisable lipid structures with multi-objective models to optimise transfection & tissue selectivity
Pengbo Guo